Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

INTRODUCTION: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A limited number of preclinical studies have detailed these EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasconcelos, Pedro E.N.S., Kobayashi, Ikei S., Kobayashi, Susumu S., Costa, Daniel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959160/
https://www.ncbi.nlm.nih.gov/pubmed/33728415
http://dx.doi.org/10.1016/j.jtocrr.2020.100105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959160/
https://www.ncbi.nlm.nih.gov/pubmed/33728415
http://dx.doi.org/10.1016/j.jtocrr.2020.100105

Ejemplares similares